subscribeSubscribe
Gilead shows $4.3B liver drug improves outcomes out to 2 years

Gilead shows $4.3B liver drug improves outcomes out to 2 years
Nick Paul Taylor FIERCE BIOTECH
05 Jun 2024
Share Share
Gilead: Seladelpar Sustained Efficacy/Safety Profile In PBC

Gilead: Seladelpar Sustained Efficacy/Safety Profile In PBC
BUSINESSWIRE
05 Jun 2024
Share Share
Gilead liver disease med still delivers ahead of FDA verdict

Gilead liver disease med still delivers ahead of FDA verdict
James Waldron FIERCE BIOTECH
20 May 2024
Share Share
Seladelpar Shows Liver, Itch Improvements In PBC

Seladelpar Shows Liver, Itch Improvements In PBC
BUSINESSWIRE
18 May 2024
Share Share
The New England Journal Publishes Positive Phase 3 of CymaBay`s Seladelpar

The New England Journal Publishes Positive Phase 3 of CymaBay`s Seladelpar
PR NEWSWIRE
21 Feb 2024
Share Share
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
PRESS RELEASE
13 Feb 2024
Share Share
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar
PR NEWSWIRE
12 Feb 2024
Share Share
Published Data Showes Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement

Published Data Showes Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement
PR NEWSWIRE
03 Jan 2024
Share Share
CymaBay Submits NDA for Seladelpar for Treatment of Primary Biliary Cholangitis

CymaBay Submits NDA for Seladelpar for Treatment of Primary Biliary Cholangitis
PR NEWSWIRE
15 Dec 2023
Share Share
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results

CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results
PR NEWSWIRE
13 Nov 2023
Share Share